TIGIT and acute myeloid leukemia: Subsequently, we compared the contribution coefficient analysis of the NKG2D/TIGIT co-expressing subpopulation in Vδ1 and found that the contribution coefficient of the NKG2D+TIGIT− Vδ1 cell subset was the highest, with the best prognosis in AML patients (Figure 4C).